IRIS
PICCIOTTO, ANTONINO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 11.307
AS - Asia 365
SA - Sud America 60
NA - Nord America 42
AF - Africa 11
Totale 11.785
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 11.298
SG - Singapore 168
CN - Cina 90
VN - Vietnam 84
BR - Brasile 37
US - Stati Uniti d'America 28
AR - Argentina 14
MX - Messico 11
HK - Hong Kong 9
IQ - Iraq 5
ZA - Sudafrica 5
EC - Ecuador 3
MA - Marocco 3
BD - Bangladesh 2
BY - Bielorussia 2
CA - Canada 2
ID - Indonesia 2
PE - Perù 2
PS - Palestinian Territory 2
RU - Federazione Russa 2
VE - Venezuela 2
CL - Cile 1
CO - Colombia 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
IE - Irlanda 1
IN - India 1
JO - Giordania 1
KE - Kenya 1
LT - Lituania 1
MD - Moldavia 1
NL - Olanda 1
RW - Ruanda 1
TR - Turchia 1
UA - Ucraina 1
Totale 11.785
Salva come PNG Salva come JPEG
Città #
Genova 7.457
Genoa 2.229
Rapallo 954
Vado Ligure 647
Singapore 61
Ho Chi Minh City 33
Beijing 23
Hanoi 15
Bordighera 11
Hong Kong 9
Ashburn 8
Mexico City 8
Da Nang 6
Los Angeles 6
Orem 4
Tianjin 4
Bình Dương 3
Sorocaba 3
São Paulo 3
Biên Hòa 2
Cabo Frio 2
Hải Dương 2
Johannesburg 2
Minsk 2
Mosul 2
New York 2
Phoenix 2
Quito 2
Thái Nguyên 2
Toronto 2
Zhengzhou 2
Actopan 1
Al Kazimiyah 1
Amman 1
Amsterdam 1
Ankara 1
Atlanta 1
Baghdad 1
Barbacena 1
Batna City 1
Bengaluru 1
Boston 1
Brasília 1
Bắc Giang 1
Bắc Ninh 1
Cachoeira Paulista 1
Cachoeirinha 1
Caicó 1
Camaçari 1
Campinas 1
Cantanhede 1
Cape Town 1
Casablanca 1
Cascavel 1
Caxias 1
Caçador 1
Cerrito 1
Clorinda 1
Cotia 1
Culiacán 1
Dallas 1
Denver 1
Dongqu 1
Dublin 1
Durban 1
Florianópolis 1
Fuzhou 1
General Pacheco 1
Gravataí 1
Guacarí 1
Guangzhou 1
Guayaquil 1
Gustavo Adolfo Madero 1
Hangzhou 1
Ica 1
Jakarta 1
Juneau 1
Kigali 1
Kroonstad 1
Kryvyi Rih 1
Libertador General San Martín 1
Lima 1
Lomas de Zamora 1
Lấp Vò 1
Macaé 1
Maiquinique 1
Maracaibo 1
Marrakesh 1
Miguel Calmon 1
Morón 1
Nairobi 1
Neuquén 1
Ninh Bình 1
Niterói 1
Pedreiras 1
Phúc Yên 1
Phủ Lý 1
Pila 1
Pilar 1
Puente Alto 1
Totale 11.577
Salva come PNG Salva come JPEG
Nome #
Non-antigen-specific CD8(+) T suppressor lymphocytes in diseases characterized by chronic immune responses and inflammation. 253
Hepatitis G virus infection in haemodialysis and in peritoneal dialysis patients. 206
A new assay for hepatitis C virus (HCV) core antigen detection: an alternative to nucleic acid technologies in positive or indeterminate anti-HCV subjects? 203
Epidemiological and clinical features of hepatitis delta in HBsAg-positive patients by HIV status. 189
Autoimmune intrahepatic cholangiopathy associated with antiphospholipid antibody syndrome 188
Circadian monitoring of gastric juice mutagenicity. 181
'Emergency exit' of bone-marrow-resident CD34+ DNAM-1 bright CXCR4+-committed lymphoid precursors during chronic infection and inflammation 181
Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response? 174
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study 173
S-adenosil-L-methionine is able to reverse the immunosuppressive effects of chenodeoxycholic acid in vitro. 172
Activating NK cell receptor expression/function (NKp30, NKp46, DNAM-1) during chronic viraemic HCV infection is associated with the outcome of combined treatment. 166
Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy 165
Behavior of soluble HLA-A, -B, -C and HLA-G molecules in patients with chronic hepatitis C virus infection undergoing pegylated interferon-α and ribavirin treatment: potential role as markers of response to antiviral therapy 165
Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis 165
Circadian reduction of chromium in the gastric environment. 163
Peripheral blood serum markers for apoptosis and liver fibrosis: Are they trustworthy indicators of liver realness? 161
Anti-hepatitis C virus antibodies and hepatitis C virus viraemia in haemodialysis patients 159
Mutagenicity of cimetidine in nitrite-enriched human gastric juice. 156
A case of drug rash with eosinophilia and systemic symptoms (DRESS) induced by telaprevir associated with HHV-6 active infection 156
T cells from patients with chronic liver diseases: abnormalities in PHA-induced expression of HLA class II antigens and in autologous mixed-lymphocyte reactions. 155
Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. 152
Biopsychosocial predictors of interferon-related depression in patients with Hepatitis C 152
Successful antiviral therapy determines a significant decrease in squamous cell carcinoma antigen-associated (SCCA) variants' serum levels in anti-HCV positive cirrhotic patients. 149
Comparison between laparoscopy, ultrasonography, and computed tomography in widespread and localized liver diseases. 148
Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients 147
Soluble apoptosis molecules in primary biliary cirrhosis: analysis and commitment of the Fas and tumour necrosis factor-related apoptosis-inducing ligand systems in comparison with chronic hepatitis C. 145
Antiviral activity of amantadine in elderly patients with chronic hepatitis C 144
Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis 143
Clearance kinetics of hepatitis C virus under different antiviral therapies. 139
Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. 138
Increased beta2-microglobulin-free HLA class I heavy chain serum levels in the course of immune responses to viral antigens and to mismatched HLA antigens. 137
Clinical and virological survey of patients with hepatitis B surface antigen in an Italian region: clinical considerations and disease burden 136
A single-blind pilot study comparing standard and half bedtime doses of ranitidine in the short-term healing of duodenal ulcer. 136
Interferon retreatment in chronic hepatitis C: wich patients to choose, and what schedule to use 134
Inherent transcriptional signatures of NK cells are associated with response to IFNΑ+rivabirin therapy in patients with Hepatitis C Virus 134
Liver transplantation in type III von Willebrand disease 132
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 132
Single bedtime dose of famotidine: assessment of its antisecretory action by 24-hour intragastric pH monitoring. 131
Long-term interferon alfa-2b retreatment of relapsing patients with chronic hepatitis C. 129
Monotherapy with Pegylated Interferon Alpha-2a in Hemodialyzed Patients with Chronic Hepatitis C 128
Are clinical patterns of dyspepsia a valid guideline for appropriate use of endoscopy? A report on 2253 dyspeptic patients. 127
HOMA, BMI, and serum leptin levels variations during antiviral treatment suggest virus-related insulin resistance in noncirrhotic, nonobese, and nondiabetic chronic hepatitis C genotype 1 patients 127
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels 127
Pegylated interferon and ribavirin in re-treatment of responder-relapser HCV patients. 126
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. 126
Continuous lamivudine treatment in an OLT patient despite the appearance of HBV resistant strain: longitudinal analysis. 125
Porphyrin Elevation in a Patient on Treatment With Simeprevir: Could It Be a Possible Explanation for Simeprevir-Associated Photosensitivity? 125
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 125
Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. 124
Predictive factors for response to Peginterferon-Alpha and ribavirin treatment of chronic HCV infection in patients aged 65 years and more 124
Prevalence and Undertreatment of Prothrombotic Risk in Advanced Forms of Liver Disease 124
Medical report type in liver transplantation as a quality system document: new prospects for computerization. 123
Virological and biochemical responses to interferon-a in chronic hepatitis C 123
A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in Italy 119
TT virus infection in haemodialysis patients 117
Effects of Interferon therapy on monoethylglycinexylidide formation in patients with chronic active hepatitis C 116
Elevations in ALT levels late the course of antiviral therapy in HCV-RNA negative patients are associated with virological relapse 115
Prospective evaluation of primary infection due to HCV, HGV or TTV in children with newly diagnosed neoplasia. 115
Soluble tumor necrosis factor-related ligand (sTRAIL) levels and kinetics during antiviral treatment in chronic hepatitis C 115
Chronic hepatitis C. New therapeutic strategies. 115
Serum lamivudine levels in the presence of a lamivudine-resistant HBV mutant 114
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies 114
Hepatic Elastometry and Glissonian Line in the Assessment of Liver Fibrosis 113
Macroamylasemia: a possible cause of unexplained hyperamylasemia in rheumatoid arthritis. 112
Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. 112
Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin. 111
Amantadine: a different approach. 110
Hepatitis C in the elderly: A multicentre cross-sectional study by the Italian Association for the Study of the Liver 107
Use of Victoria blue in the detection of intrahepatocyte HBs Ag: comparison with other methods. 106
Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension. 105
The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience 105
Diabetic hepatosclerosis presenting with severe cholestasis 104
Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. 103
EVALUATION OF HEPATIC FIBROSIS WITH TRANSIENT ELASTOGRAPHY (FIBROSCAN) AND APRI SCORE IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ITS CORRELATION WITH PULMONARY, CARDIAC, RENAL AND ESOPHAGEAL INVOLVEMENT 102
First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness 100
Biochemical scores could reflect histological activity in chronic hepatitis C 95
Initial high dose of lamivudine delays the appearance of viral resistance in chronic hepatitis B patients 94
Serum intercellular adhesion molecule-1 and long-term response to IFN-alpha2b therapy in chronic hepatitis C 94
Hepatitis C recurrence: Split liver versus whole size graft. 90
Evaluation of a new hepatitis C virus sequecing assay as a routine method for genotyping 90
Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls. 86
Probability of non-response during interferon therapy in patients with chronic hepatitis C 85
Therapeutic management of chronic hepatitis B in clinical Practice: a region-wide survey. 85
Predictability and survival in liver replantransplantation: Monocentric experience 83
Postprandial serum bile acids after ursodeoxycholic acid. A possible test of intestinal absorption? 77
Metabolic activation of food hepatocarcinogens in hepatitis B virus-infected humans and animals. 76
Iodized oil pleural effusion in a patient previously treated with transarterial chemoembolization for hepatocellular carcinoma 76
Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation 76
Effect of a common missense variant in LIPA gene on fatty liver disease and lipid phenotype: New perspectives from a single-center observational study 76
Pityriasis rosea in a hepatitis b-positive patient treated with pegylated interferon α2a: Report of a case and review of the literature 74
Detection of anti-HCV IgM antibodies in patients with chronic hepatitis C treated with interferon 72
Soluble beta2-mu-associated and beta2-mu-free HLA class I heavy chain serum levels in interferon-alpha nonresponder chronic hepatitis C patients. Markers of immune activation, and response to antiviral retreatment. 68
Individualized treatment of genotype 1 Naïve patients: An Italian multicenter field practice experience 55
Role of dietary intervention in patients with metabolic syndrome and {NAFLD}-{NASH} 52
Totale 11.877
Salva come PNG Salva come JPEG
Categoria #
all - tutte 36.681
article - articoli 36.242
book - libri 0
conference - conferenze 439
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 73.362
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021445 0 0 0 0 0 70 24 81 55 100 54 61
2021/20221.168 36 63 73 145 47 81 69 262 92 104 47 149
2022/20231.134 115 105 11 107 175 192 3 95 205 11 105 10
2023/2024463 19 80 8 59 32 63 25 30 30 9 40 68
2024/20251.574 52 106 35 108 248 154 138 279 51 59 148 196
2025/20261.162 374 53 122 191 347 75 0 0 0 0 0 0
Totale 11.877